{"description":"At each visit the investigator had to document any occurrence of AEs and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to the survey treatment.","eventGroups":[{"deathsNumAffected":1,"deathsNumAtRisk":31,"description":"Adult participants with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) were received brentuximab vedotin (genetic recombination) 1.8 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every three weeks (up to 12 months). The dose should be reduced appropriately depend on the participant's condition. Participants received interventions as part of routine medical care.","id":"EG000","otherNumAffected":18,"otherNumAtRisk":31,"seriousNumAffected":8,"seriousNumAtRisk":31,"title":"Adult Participants With PTCL-NOS"},{"deathsNumAffected":5,"deathsNumAtRisk":35,"description":"Adult participants with angioimmunoblastic T-cell lymphoma (AITL) were received brentuximab vedotin (genetic recombination) 1.8 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every three weeks (up to 12 months). The dose should be reduced appropriately depend on the participant's condition. Participants received interventions as part of routine medical care.","id":"EG001","otherNumAffected":14,"otherNumAtRisk":35,"seriousNumAffected":12,"seriousNumAtRisk":35,"title":"Adult Participants With AITL"},{"deathsNumAffected":2,"deathsNumAtRisk":14,"description":"Adult participants with adult T-cell leukemia/lymphoma (ATLL) were received brentuximab vedotin (genetic recombination) 1.8 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every three weeks (up to 12 months). The dose should be reduced appropriately depend on the participant's condition. Participants received interventions as part of routine medical care.","id":"EG002","otherNumAffected":6,"otherNumAtRisk":14,"seriousNumAffected":2,"seriousNumAtRisk":14,"title":"Adult Participants With ATLL"},{"deathsNumAffected":0,"deathsNumAtRisk":6,"description":"Adult participants with the other PTCL (peripheral T-cell lymphoma \\[PTCL\\] subtypes other than anaplastic large-cell lymphoma \\[ALCL\\] \\[not surveyed\\], PTCL-NOS, AITL, and ATLL) were received brentuximab vedotin (genetic recombination) 1.8 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every three weeks (up to 12 months). The dose should be reduced appropriately depend on the participant's condition. Participants received interventions as part of routine medical care.","id":"EG003","otherNumAffected":4,"otherNumAtRisk":6,"seriousNumAffected":1,"seriousNumAtRisk":6,"title":"Adult Participants With Other PTCL"},{"deathsNumAffected":0,"deathsNumAtRisk":4,"description":"Pediatric participants with peripheral T-cell lymphoma (PTCL) were received brentuximab vedotin (genetic recombination) 1.8 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every three weeks (up to 12 months). The dose should be reduced appropriately depend on the participant's condition. Participants received interventions as part of routine medical care.","id":"EG004","otherNumAffected":2,"otherNumAtRisk":4,"seriousNumAffected":3,"seriousNumAtRisk":4,"title":"Pediatric Participants With PTCL"},{"deathsNumAffected":0,"deathsNumAtRisk":4,"description":"Pediatric participants with Hodgkin lymphoma (HL) were received brentuximab vedotin (genetic recombination) 1.8 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every three weeks (up to 12 months). The dose should be reduced appropriately depend on the participant's condition. Participants received interventions as part of routine medical care.","id":"EG005","otherNumAffected":2,"otherNumAtRisk":4,"seriousNumAffected":2,"seriousNumAtRisk":4,"title":"Pediatric Participants With HL"}],"frequencyThreshold":"5.0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":1,"numAtRisk":4}],"term":"Otitis media acute"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":1,"numAtRisk":4}],"term":"Upper respiratory tract infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"COVID-19"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":1,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Hyponatraemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":1,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Peripheral motor neuropathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":31},{"groupId":"EG001","numAffected":9,"numAtRisk":35},{"groupId":"EG002","numAffected":2,"numAtRisk":14},{"groupId":"EG003","numAffected":1,"numAtRisk":6},{"groupId":"EG004","numAffected":2,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Peripheral sensory neuropathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":1,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"VIth nerve disorder"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":1,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Cholelithiasis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":1,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Rash"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":1,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Rash papular"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":1,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Pruritus allergic"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Malaise"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":1,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Pyrexia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":1,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Blood lactate dehydrogenase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":1,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Blood alkaline phosphatase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":35},{"groupId":"EG002","numAffected":2,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":1,"numAtRisk":4}],"term":"Neutrophil count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":1,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Alanine aminotransferase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":1,"numAtRisk":6},{"groupId":"EG004","numAffected":1,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Aspartate aminotransferase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":1,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Gamma-glutamyltransferase increased"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Bronchitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":1,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Sepsis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":1,"numAtRisk":4}],"term":"Vascular device infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"COVID-19"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":4,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Angioimmunoblastic T-cell lymphoma"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":2,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Peripheral T-cell lymphoma unspecified"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Metastases to central nervous system"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":1,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Febrile neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":4,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":1,"numAtRisk":4},{"groupId":"EG005","numAffected":1,"numAtRisk":4}],"term":"Myelosuppression"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":1,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Pancytopenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Diabetes mellitus"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Hypokalaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Decreased appetite"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Peripheral sensory neuropathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":1,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Posterior reversible encephalopathy syndrome"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Interstitial lung disease"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":1,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Diverticulum intestinal haemorrhagic"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":1,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Cholecystitis acute"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Dermatitis bullous"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Neutrophil count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Platelet count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA/J v26.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":35},{"groupId":"EG002","numAffected":0,"numAtRisk":14},{"groupId":"EG003","numAffected":0,"numAtRisk":6},{"groupId":"EG004","numAffected":0,"numAtRisk":4},{"groupId":"EG005","numAffected":0,"numAtRisk":4}],"term":"Blood creatinine increased"}],"timeFrame":"Up to 12 Months"}